Jan Östergren

33.8k total citations · 9 hit papers
140 papers, 19.7k citations indexed

About

Jan Östergren is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Physiology. According to data from OpenAlex, Jan Östergren has authored 140 papers receiving a total of 19.7k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Cardiology and Cardiovascular Medicine, 38 papers in Surgery and 21 papers in Physiology. Recurrent topics in Jan Östergren's work include Blood Pressure and Hypertension Studies (40 papers), Heart Failure Treatment and Management (33 papers) and Cardiovascular Function and Risk Factors (24 papers). Jan Östergren is often cited by papers focused on Blood Pressure and Hypertension Studies (40 papers), Heart Failure Treatment and Management (33 papers) and Cardiovascular Function and Risk Factors (24 papers). Jan Östergren collaborates with scholars based in Sweden, United Kingdom and United States. Jan Östergren's co-authors include Salim Yusuf, John J.V. McMurray, Karl Swedberg, Eric L. Michelson, Bertil Olofsson, Marc A. Pfeffer, Christopher B. Granger, Peter Held, Mark J. Caulfield and Jesper Mehlsen and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Jan Östergren

139 papers receiving 18.6k citations

Hit Papers

Prevention of coronary an... 2003 2026 2010 2018 2003 2003 2005 2003 2003 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
    2003 2.7k citations Hans Wedel, Gareth Beevers et al. The Lancet profile →
  2. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    2003 2.0k citations Salim Yusuf, Marc A. Pfeffer et al. The Lancet profile →
  3. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
    2005 1.9k citations Hans Wedel, Mark J. Caulfield et al. The Lancet profile →
  4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    2003 1.8k citations John J.V. McMurray, Jan Östergren et al. The Lancet profile →
  5. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    2003 1.3k citations Marc A. Pfeffer, Karl Swedberg et al. The Lancet profile →
  6. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    2003 1.1k citations Christopher B. Granger, John J.V. McMurray et al. The Lancet profile →
  7. CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL
    2003 794 citations John J.V. McMurray, Jan Östergren et al. The Lancet profile →
  8. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
    2006 733 citations Marc A. Pfeffer, Karl Swedberg et al. profile →
  9. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    2008 503 citations Mark C. Petrie, Jan Östergren et al. European Heart Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jan Östergren 14.2k 5.6k 4.7k 2.0k 1.7k 140 19.7k
Eoin OʼBrien 15.9k 1.1× 4.1k 0.7× 7.1k 1.5× 1.2k 0.6× 1.6k 1.0× 268 21.5k
Peter Sever 9.8k 0.7× 5.1k 0.9× 7.0k 1.5× 1.2k 0.6× 2.5k 1.5× 193 16.8k
Prakash Deedwania 11.4k 0.8× 5.9k 1.0× 5.6k 1.2× 1.1k 0.6× 1.5k 0.9× 390 19.4k
Björn Dahlöf 13.4k 0.9× 6.0k 1.1× 2.8k 0.6× 858 0.4× 1.1k 0.7× 172 16.7k
Michael A. Weber 16.8k 1.2× 6.5k 1.2× 3.6k 0.8× 1.3k 0.6× 719 0.4× 499 21.9k
Franz H. Messerli 16.2k 1.1× 5.5k 1.0× 3.2k 0.7× 1.4k 0.7× 766 0.5× 415 22.9k
Gareth Beevers 7.7k 0.5× 4.4k 0.8× 3.8k 0.8× 978 0.5× 1.5k 0.9× 60 12.5k
Barry R. Davis 13.3k 0.9× 5.9k 1.1× 9.4k 2.0× 2.1k 1.0× 3.0k 1.8× 256 25.7k
Rafael Díaz 12.7k 0.9× 3.9k 0.7× 3.1k 0.7× 1.2k 0.6× 1.0k 0.6× 130 18.4k
Gordon T. McInnes 8.6k 0.6× 5.3k 0.9× 4.3k 0.9× 804 0.4× 1.8k 1.1× 123 13.4k

Countries citing papers authored by Jan Östergren

Since Specialization
Citations

This map shows the geographic impact of Jan Östergren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Östergren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Östergren more than expected).

Fields of papers citing papers by Jan Östergren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Östergren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Östergren. The network helps show where Jan Östergren may publish in the future.

Co-authorship network of co-authors of Jan Östergren

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Östergren. A scholar is included among the top collaborators of Jan Östergren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Östergren. Jan Östergren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Svensson, Per, et al.. (2020). Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease—A randomized controlled trial. SHILAP Revista de lepidopterología. 8. 100074–100074. 6 indexed citations
2.
Ehrenberg, Anna, et al.. (2017). Physicians’ and nurses’ perceptions of patient safety risks in the emergency department. International Emergency Nursing. 33. 14–19. 57 indexed citations
3.
Rogers, Jennifer K., Stuart Pocock, John J.V. McMurray, et al.. (2014). Corrigendum to ‘Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved’ [ Eur J Heart Fail 2014;16:33–40]. European Journal of Heart Failure. 16(5). 592–592. 3 indexed citations
4.
Rogers, Jennifer K., Stuart Pocock, John J.V. McMurray, et al.. (2013). Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-Preserved. European Journal of Heart Failure. 16(1). 33–40. 151 indexed citations
5.
Hawkins, Nathaniel M., Duolao Wang, Mark C. Petrie, et al.. (2010). Baseline Characteristics and Outcomes of Patients with Heart Failure Receiving Bronchodilators in the CHARM Programme. European Journal of Heart Failure. 12(6). 557–565. 55 indexed citations
6.
Granger, Bradi B., Inger Ekman, Christopher B. Granger, et al.. (2009). Adherence to Medication According to Sex and Age in the CHARM Programme. European Journal of Heart Failure. 11(11). 1092–1098. 108 indexed citations
7.
Meredith, Peter, Jan Östergren, Inder S. Anand, et al.. (2008). Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology. 52(24). 2000–2007. 33 indexed citations
8.
Nilsson, Mikael, Gunilla Bolinder, Claes Held, et al.. (2008). Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. BMC Medical Education. 8(1). 25–25. 60 indexed citations
9.
Arpegård, Johannes, Jan Östergren, Ulf dé Fairé, Lotta Hansson, & Per Svensson. (2008). Cystatin C—A marker of peripheral atherosclerotic disease?. Atherosclerosis. 199(2). 397–401. 48 indexed citations
10.
Hawkins, Nathaniel M., Duolao Wang, John J.V. McMurray, et al.. (2007). Prevalence and Prognostic Impact of Bundle Branch Block in Patients with Heart Failure: Evidence from the CHARM Programme. European Journal of Heart Failure. 9(5). 510–517. 45 indexed citations
11.
Persson, Hans, Eva Lonn, Magnus Edner, et al.. (2007). Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. Journal of the American College of Cardiology. 49(6). 687–694. 214 indexed citations
12.
Östergren, Jan, N. Poulter, Björn Dahlöf, et al.. (2006). The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb (ASCOT-BPLA): effects in patients with type 2 diabetes. Diabetologia. 49. 136–137. 6 indexed citations
13.
O’Meara, Eileen, Eldrin F. Lewis, C. B. Granger, et al.. (2005). Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure. 7(4). 650–656. 21 indexed citations
14.
Solomon, Scott D., Bertil Olofsson, Peter Finn, et al.. (2004). 1069-113 Cause of death across full spectrum of ventricular function in patients with heart failure: The CHARM study. Journal of the American College of Cardiology. 43(5). A180–A180. 2 indexed citations
15.
16.
17.
Östergren, Jan. (2003). Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal. 25(1). 17–24. 208 indexed citations
18.
Björholt, Ingela, Fredrik Andersson, Thomas Kahan, & Jan Östergren. (2002). The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study. Journal of Internal Medicine. 251(6). 508–517. 26 indexed citations
19.
Kennedy, J. W., Mogensen Ce, Susan Ball, et al.. (2001). WHAT IS THE RELEVANCE OF THE HOPE STUDY IN GENERAL PRACTICE?. International Journal of Clinical Practice. 55(7). 449–457. 2 indexed citations
20.
Östergren, Jan, et al.. (1984). MICROVASCULAR REACTIVITY IN LONG DURATION TYPE-1 DIABETICS WITHOUT MICROVASCULAR COMPLICATIONS. UCL Discovery (University College London). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eoin OʼBrien Breakdown of academic impact, for papers by Peter Sever Breakdown of academic impact, for papers by Prakash Deedwania Breakdown of academic impact, for papers by Björn Dahlöf Breakdown of academic impact, for papers by Michael A. Weber Breakdown of academic impact, for papers by Franz H. Messerli Breakdown of academic impact, for papers by Gareth Beevers Breakdown of academic impact, for papers by Barry R. Davis Breakdown of academic impact, for papers by Rafael Díaz Breakdown of academic impact, for papers by Gordon T. McInnes
Rankless by CCL
2026